Clinical trial · Interventional
Search for Predictors of Therapeutic Response in Ovarian Carcinoma
Search for Predictors of Therapeutic Response in Patients With Carcinoma of the Ovary, the Fallopian Tube or Peritoneal Serous-type Advanced
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In order to search for predictors of response to chemotherapy in patients with ovarian carcinoma of the ovary, the fallopian tube or peritoneal serous-type advanced stage, we will define the comparative profiles of miRNA expression of serum polymorphisms and determine differential in 2 patient populations (with or without recurrence 6 months after completion of chemotherapy) with (i) the miRNA profile of serum before treatment and (ii) identification of polymorphisms or SNP (Single Nucleotide Polymorphism) in particular genes involved in the metabolism of chemotherapy agents In the case of miRNA, expression profiles will also be studied during the first course in response to chemotherapy. Indeed, the miRNA profile of serum may be different at baseline among the 2 types of populations (or non-recurrence at 6 months).
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma of the Ovary | Ovarian Carcinoma | ALIAS | 0.90 |
| Fallopian Tube Cancer | Malignant Fallopian Tube Neoplasm | ALIAS | 0.90 |
| Peritoneal Serous-type Advanced Stage | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood samples | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- OTHER
- label
- Taxol and carboplatin
- description
- blood samples in patients receiving Taxol and carboplatin chemotherapy
- interventionNames
- Other: blood samples
- type
- OTHER
- label
- Taxol, carboplatin and avastin
- description
- blood samples in patients receiving Taxol, carboplatin chemotherapy with avastin
- interventionNames
- Other: blood samples
Primary outcomes (1)
- measure
- search for predictors of response to chemotherapy
- timeFrame
- 12 months after beginning treatment
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with cancer of the ovary, peritoneum or of the fallopian tube * Stage III or IV * Cancer of serous histology * Patients of any chemotherapy naive * Patients should receive treatment with chemotherapy for first line by Taxol- Carboplatin. Avastin is authorized in concomitant. * An initial surgery or through authorized * Patients who signed informed consent * Patients over the age of 18 years Exclusion Criteria: * Patients being treated for another cancer chemotherapy and / or hormone therapy * Patients receiving other chemotherapy Taxol-carboplatin associated or not to avastin * Patients under guardianship * Previous history of pelvic radiotherapy * History of malignancy blood
References
Publications (0)
Data not yet available